{"filing":{"accession_number":"0001193125-26-384380","cik":"0001980845","ticker":"ENGNW","company_name":"enGene Therapeutics Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"engn-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526384380/engn-20260908.htm"},"events":[{"id":31793,"run_id":29192,"accession_number":"0001193125-26-384380","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses enGene's financial results for the three and nine months ended July 31, 2026, including operating expenses ($34.0 million for Q3 2026), net loss ($32.5 million or $0.47 per share), and cash position ($266.3 million). The press release attached as Exhibit 99.1 is a standard earnings announcement with financial metrics and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings releases.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":34779,"accession_number":"0001193125-26-384380","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses enGene's financial results for the three and nine months ended July 31, 2026, including operating expenses ($34.0 million for Q3 2026), net loss ($32.5 million or $0.47 per share), and cash position ($266.3 million). The press release attached as Exhibit 99.1 is a standard earnings announcement with financial metrics and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:34:37.632515+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34779,"accession_number":"0001193125-26-384380","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses enGene's financial results for the three and nine months ended July 31, 2026, including operating expenses ($34.0 million for Q3 2026), net loss ($32.5 million or $0.47 per share), and cash position ($266.3 million). The press release attached as Exhibit 99.1 is a standard earnings announcement with financial metrics and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T11:34:37.632515+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-09-08"}]}